Patents Assigned to Leiden University (Medical Center)
-
Publication number: 20130302815Abstract: The invention provides a polynucleotide comprising a reporter sequence operatively linked to a regulatory element of a gene selected from Bscl2, Srxnl, Cbr3, Ephxl, Nope, Cdknla, Perp, Pltp, Cgrefl, Ltb4r1, Btg2, Gpx2, Ltb4r2, Ddit4l, Fosl1, and Egr1, which regulatory element stimulates expression of the reporter sequence in response to a genotoxic agent or to an oxidative stress-inducing agent. The invention also provides a method of detecting a genotoxic or oxidative stress-inducing agent comprising subjecting a cell containing the polynucleotide of the invention to a test agent; and assessing the expression of the reporter sequence.Type: ApplicationFiled: September 15, 2011Publication date: November 14, 2013Applicants: ACADEMISCH ZIEKENHUIS LEIDEN also acting under the name LEIDEN UNIVERSITY MEDICAL CENTER, UNIVERSITEIT LEIDENInventors: Bob Van de Water, Harm Vrieling
-
Publication number: 20130288976Abstract: In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene, wherein a determination of the absence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject does not have a genetic predisposition to develop, and is not suffering from FSHD, and/or wherein a determination of the presence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject has a genetic predisposition to develType: ApplicationFiled: August 18, 2011Publication date: October 31, 2013Applicants: Fred Hutchinson Cancer Research Center, University of Rochester Medical Center, Leiden University Medical CenterInventors: Silvere M. van der Maarel, Stephen J. Tapscott, Rabi Tawil, Richard J.L.F. Lemmers, Linda Geng, Lauren Snider
-
Patent number: 8470785Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.Type: GrantFiled: September 27, 2011Date of Patent: June 25, 2013Assignees: St. Jude Children's Research Hospital, Leiden University Medical Center, VIB VZW and Universiteit GentInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy, Fangyi Zhu
-
Publication number: 20130045198Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: June 25, 2012Publication date: February 21, 2013Applicants: LEIDEN UNIVERSITY MEDICAL CENTER (LUMC), ACTING ON BEHALF OF ACADEMIC HOSPITAL LEIDEN (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Publication number: 20120264692Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 11, 2011Publication date: October 18, 2012Applicants: Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Publication number: 20120244625Abstract: The invention provides the use of 2-picoline borane (2-PB) for the reductive amination of carbohydrates, especially glycans from book plasma, wherein the concentration of 2-PB is less than the concentration of NaBH(OAc)3 or NaBH3CN required to obtain comparable conversion of the carbohydrate. It also describes a process for labelling a carbohydrate, the process comprising contacting the carbohydrate with a labelling agent, e.g. 2-aminobenzoic acid, 2-aminobenzamide, APTS, etc. in the presence of 2-picoline borane as reducing agent. Labelling the carbohydrate in this way facilitates detection using HPLC techniques, e.g. HILIC-HPLC-FL, HILIC-ESI-IT-MS, or capillary electrophoresis.Type: ApplicationFiled: September 27, 2010Publication date: September 27, 2012Applicant: LEIDEN UNIVERSITY MEDICAL CENTERInventors: Lucia Renee Ruhaak, Manfred Wuhrer
-
Publication number: 20120108651Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment (particularly for reducing the risk of venous thrombosis). For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: November 1, 2011Publication date: May 3, 2012Applicants: Leiden University Medical Center (LUMC) Acting On Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Publication number: 20120039864Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: February 8, 2011Publication date: February 16, 2012Applicants: Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Publication number: 20110008287Abstract: The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the anogenital tract, such as HPV induced vulvar, cervical, vaginal, penile and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+ response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.Type: ApplicationFiled: September 10, 2010Publication date: January 13, 2011Applicant: Leiden University Medical CenterInventors: Sjoerd Hendricus VAN DER BURG, Rienk Offringa, Cornelis Johannes Maria Melief, Theodorus Jozef Maria Helmerhorst
-
Patent number: 7807369Abstract: The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.Type: GrantFiled: April 25, 2006Date of Patent: October 5, 2010Assignee: Leiden University Medical CenterInventors: Sjoerd Hendricus van der Burg, Rienk Offringa, Cornelis Johannes Maria Melief, Theodorus Jozef Maria Helmerhorst
-
Publication number: 20090220473Abstract: The invention relates to the field of stem cell transplantations, immunotherapy and prophylaxis of neoplastic disease. Provided are peptides comprising an amino acid sequence encoded by an open reading frame as present in the nucleotide sequence of a transcript of a naturally occurring hADIR allele, wherein the amino acid sequence comprises a polymorphic MHC class I or II minor histocompatibility binding peptide.Type: ApplicationFiled: February 22, 2007Publication date: September 3, 2009Applicant: Leiden University Medical CenterInventors: Cornelis Adreanus Maria Van Bergen, Michel George Dideric Kester, Petrus Antonius Van Veelen, Johan Herman Frederik Falkenburg
-
Patent number: 7550138Abstract: The invention relates to the production of new Plasmodium mutants which are defective in the expression of the protein P36p. These mutants are unable to cause malaria, yet they can be used as vaccine, giving long lasting protection against infections with wild-type Plasmodium.Type: GrantFiled: August 14, 2007Date of Patent: June 23, 2009Assignees: Leiden University Medical Center, Stichting Katholieke Universiteit NijmegenInventors: Andrew Paul Waters, Christofel Jan Janse, Melissa Ruth van Dijk, Robert W. Sauerwein
-
Publication number: 20090028874Abstract: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV protein directed immunity as a model.Type: ApplicationFiled: December 24, 2003Publication date: January 29, 2009Applicant: LEIDEN UNIVERSITY MEDICAL CENTERInventors: Sjoerd Henricus Van Der Burg, Jan Wouter Drijfhout
-
Patent number: 6611704Abstract: For the early detection of blindness-causing diabetic retinopathy, an apparatus for measuring the autofluorescence of the cornea of an eye, comprising means for tangentially illuminating the cornea, means for receiving the autofluorescent radiation generated in the cornea by this illumination, and means for processing the measured autofluorescent radiation, wherein the means for tangentially illuminating the cornea comprises at least one light source which radiates blue light and at least one filter which transmits at least a part of the blue light in a light path to the cornea, and the means for receiving the autofluorescent radiation generated in the cornea comprises at least one filter which transmits green light.Type: GrantFiled: July 27, 2000Date of Patent: August 26, 2003Assignee: Leiden University (Medical Center)Inventors: Jasper Anton van Best, Franco Docchio